Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies

Bibliography

• Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood (ASH Annual Meeting Abstracts) 2007;109:944-50
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010;116:5568-74
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012;120:2032-41
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: A historical perspective. Pharmacol Ther 2012;136(3):334-42
   PubMed Web of Science ®Google Scholar
• Löffler A, Kufer P, Lutterbuse R, et al. A recombinant bispecific single-chain antibody, CD19xCD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood (ASH Annual Meeting Abstracts) 2000;95(6):2098-103
   PubMed Web of Science ®Google Scholar
• Wolf E, Hofmeister R, Kufer P, et al. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005;10(18):1237-44
   PubMed Web of Science ®Google Scholar
• Offner S, Hofmeister R, Romaniuk A, et al. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006;43:763-71
   PubMed Web of Science ®Google Scholar
• Löffler A, Gruen M, Wuchter C, et al. Efficient elimination of chronic lymphocytic leukemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 2003;17:900-9
   PubMed Web of Science ®Google Scholar
• Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood (ASH Annual Meeting Abstracts) 2012;119(26):6226-33
   PubMed Web of Science ®Google Scholar
• Dreier T, Lorenczerski G, Brandl C, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002;100:690-7
   PubMed Web of Science ®Google Scholar
• Hoffman P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005;115:98-104
   PubMed Web of Science ®Google Scholar
• Gruen M, Bommert K, Bargou RC. T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol Immunother 2004;53:625-32
   PubMed Web of Science ®Google Scholar
• d’Argouges S, Wissing S, Brandl C, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009;33(3):465-73
   PubMed Web of Science ®Google Scholar
• Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012;1:36
   PubMedGoogle Scholar
• Piccaluga PP, Arpinati M, Candoni A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma 2011;52(2):325-7
   PubMed Web of Science ®Google Scholar
• Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011;52(6):1098-107
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Bargou R, Ruttinger D, et al. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 2009;50(6):886-91
   PubMed Web of Science ®Google Scholar
• Hijazi Y, Klinger M, Schub A, et al. Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL). J Clin Oncol 2013(Suppl):abstract 3051
   Google Scholar
• Brandl C, Haas C, d’Argouges S, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother 2007;56:1551-63
   PubMed Web of Science ®Google Scholar
• Blincyto ® [package insert]. Amgen Inc; Thousand Oaks, CA: 2014
   Google Scholar
• Wu B, Hijazi Y, Wolf A, et al. Pharmacokinetics (PK) of blinatumomab and its clinical implications. J Clin Oncol 2013(Suppl):abstract 3048
   Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-7
   PubMed Web of Science ®Google Scholar
• Goebeler M, Viardot A, Noppeney R, et al. Blinatumomab (CD3/CD19 BiTE® Antibody) results in high response rate in patients with relapsed non-Hodgkin’s lymphoma (NHL) including MCL and DLBCL. Ann Oncol 2011;22(4):abstract 068
   Google Scholar
• Goebeler ME, Viardot A, Kufer P, et al. Final results from a phase 1 study of blinatumomab in patients with relapsed/refractory Non-Hodgkin’s lymphoma. Hematol Oncol 2013;31(Suppl 1):abstract 302
   Google Scholar
• Viardot A, Goebeler M, Nopponey R, et al. Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2011;abstract 1637. Available from: https://ash.confex.com/ash/2011/webprogram/Paper36931.html
   Google Scholar
• Viardot A, Goebeler M, Scheele J, et al. Treatment of patients with non-Hodgkin lymphoma (NHL) with CD19/CD3 bispecific antibody blinatumomab (MT103): double-step dose increase to continuous infusion of 60 µg/m2/d is tolerable and highly effective. Blood (ASH Annual Meeting Abstracts) 2010;116(21):abstract 2880
   Google Scholar
• Viardot A, Goebeler M, Hess G, et al. Treatment of relapsed/refractory diffuse large B-cell lymphoma with the bispecific T-cell engager (BiTE®) antibody construct blinatumomab: primary analysis results from an open-label, phase 2 study. Blood (ASH Annual Meeting Abstracts) 2014;abstract 4460. Available from: https://ash.confex.com/ash/2014/webprogram/Paper68589.html
   Google Scholar
• Topp MS, Gökbuget N, Zugmaier G, et al. Phase II Trial of the Anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014;32(36):4134-40
   PubMed Web of Science ®Google Scholar
• Goekbuget N, Dombret H, Bonifacio M, et al. BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 2014;abstract 379. Available from: https://ash.confex.com/ash/2014/webprogram/Paper67851.html
   Google Scholar
• Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29(18):2493-8
   PubMed Web of Science ®Google Scholar
• Brüggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006;107(3):1116-23
   PubMed Web of Science ®Google Scholar
• Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009;113(18):4153-62
   PubMed Web of Science ®Google Scholar
• Raff T, Gökbuget N, Lüschen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007;109(3):910-15
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012;120(9):1868-76
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Zugmaier et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120(26):5185-7
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Gökbuget N, Viardot A, et al. Long-term survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) who achieved minimal residual disease (MRD) response following anti-CD19 BiTE® blinatumomab. Blood (ASH Annual Meeting Abstracts) 2014;abstract 2287. Available from: https://ash.confex.com/ash/2014/webprogram/Paper69269.html
   Google Scholar
• Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16:57-66
   PubMed Web of Science ®Google Scholar
• Stein A, Topp M, Gökbuget N, et al. allogeneic hematopoietic stem cell transplantation following anti-CD19 BiTE® blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 2014;abstract 965. Available from: https://ash.confex.com/ash/2014/webprogram/Paper70180.html
   Google Scholar
• Handgretinger R, Zugmaier G, Henze G, et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2011;25:181-4
   PubMed Web of Science ®Google Scholar
• Schlegel P, Lang P, Zugmaier G, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 2014;99(7):1212-19
   PubMed Web of Science ®Google Scholar
• von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase 1/2 study in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) Receiving blinatumomab treatment. Blood (ASH Annual Meeting Abstracts) 2014;abstract 2292. Available from: https://ash.confex.com/ash/2014/webprogram/Paper69576.html
   Google Scholar
• Gore L, Locatelli F, Zugmaier G, et al. Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 2014;abstract 3703. Available from: https://ash.confex.com/ash/2014/webprogram/Paper69686.html
   Google Scholar
• Wong R, Pepper C, Brennan P, et al. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica 2013;98(12):1930-8
   PubMed Web of Science ®Google Scholar
• Golay J, D’Amico A, Borleri G, et al. A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy. J Immunol 2014;193:4739-47
   PubMed Web of Science ®Google Scholar
• Jadidi-Niaragh F, Yousefi M, Memarian A, et al. Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression. Cancer Invest 2013;31:121-31
   PubMed Web of Science ®Google Scholar
• Kita K, Nakase K, Miwa H, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992;80(2):470-7
   PubMed Web of Science ®Google Scholar
• Brandt JT, Tisone JA, Bohman JE, Theil KS. Aberrant expression of CD19 as a marker of monocytic lineage in acute myelogenous leukemia. Am J Clin Pathol 1997;107(3):283-91
   PubMed Web of Science ®Google Scholar
• Ball ED, Davis RB, Griffin JD, et al. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 1991;77(10):2242-50
   PubMed Web of Science ®Google Scholar
• Solary E, Casasnovas RO, Campos L, et al. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter survival. Leukemia 1992;6(5):393-9
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Gudgeon CJ, Harrington KH, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 2014;123(4):554-61
   PubMed Web of Science ®Google Scholar
• Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014;123(3):356-65
   PubMed Web of Science ®Google Scholar
• Aigner M, Feulner J, Schaffer S, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 2013;27(5):1107-15
   PubMed Web of Science ®Google Scholar
• Bonifant CL, Torres D, Velasquez MP, et al. CD123-engager T cells as a novel immunotherapeutic for AML. Blood (ASH Annual Meeting Abstracts) 2014;abstract 3762. Available from: https://ash.confex.com/ash/2014/webprogram/Paper69216.html
   Google Scholar
• Smith BD, Roboz GJ, Walter RB, et al. First-in man, phase 1 study of CSL362 (Anti-IL3Rα/ anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia (AML) in CR at high risk for early relapse. Blood (ASH Annual Meeting Abstracts) 2014;abstract 120. Available from: https://ash.confex.com/ash/2014/webprogram/Paper73194.html
   Google Scholar
• Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013;121(26):5154-7
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in diagnosis and management of cytokine release syndrome. Blood 2014;124(2):188-95
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Topp MS, Alekar S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J 2014;4:244
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Acute Lymphoblastic Leukemia [Version 2.2014]. [Accessed 8 Febuary 2015]
   Google Scholar
• Duell J, Dittrich M, Bedke T, et al. Crucial role of regulatory T cells in predicting the outcome of the T cell engaging antibody blinatumomab in relapsed and refractory B precursor ALL patients. Blood (ASH Annual Meeting Abstracts) 2014;abstract 2291. Available from: https://ash.confex.com/ash/2014/webprogram/Paper69981.html
   Google Scholar
• O’Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 2013;31(6):676-83
   PubMed Web of Science ®Google Scholar
• Grupp S, Maude SL, Shaw P, et al. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) have long term persistence and induce durable remissions in children with relapsed, refractory all. Blood (ASH Annual Meeting Abstracts) 2014;abstract 380. Available from: https://ash.confex.com/ash/2014/webprogram/Paper69932.html
   Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507-17
   PubMed Web of Science ®Google Scholar
• Frey NV, Levine BL, Lacey SF, et al. Refractory cytokine release syndrome in recipients of chimeric antigen receptor (CAR) T cells. Blood (ASH Annual Meeting Abstracts) 2014;abstract 2296. Available from: https://ash.confex.com/ash/2014/webprogram/Paper76315.html
   Google Scholar
• Brentjens R, Davila M, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5(177):177ra38
   PubMed Web of Science ®Google Scholar
• Park JH, Riviere I, Wang X, et al. CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL. Blood (ASH Annual Meeting Abstracts) 2014;abstract 382. Available from: https://ash.confex.com/ash/2014/webprogram/Paper76573.html
   Google Scholar
• Lee DW, Stetler-Stevenson M, Sabatino M, et al. Intent-to-treat results of a phase I trial of CD19 chimeric antigen receptor T cells using a consistent treatment regimen reveals a 67% complete response rate in relapsed, refractory acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts) 2014;124(21):abstract 381. Available from: https://ash.confex.com/ash/2014/webprogram/Paper75723.html
   Google Scholar
• Francis J, Dharmadhikari AV, Sait SN, et al. CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations. Leuk Lymphoma 2013;57(7):1517-20
   Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012;13(4):403-11
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013;119:2728-36
   PubMed Web of Science ®Google Scholar